Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2048-2058

  Dingemans, Anne Marie C ^a   Witlox, M Adhiambo ^a   Stallaert, Roland A L M ^b   Van Der Valk, Paul ^a   Postmus, Pieter E ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Westfries Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIRUBICIN; ETOPOSIDE; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; VINCRISTINE;

ADULT; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032771490     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Ginsberg, R. J., Vokes, E. E., and Raben, A. Non-small cell lung cancer. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, Ed. 5, Vol. 2, pp. 858-911. Philadelphia: J. B. Lippincott Co., 1997.
2. Ihde, D. C., Pass, H. I., and Glatstein, E. Small cell lung cancer. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, Ed. 5. Vol. 2, pp. 911-941. Philadelphia: J. B. Lippincott Co., 1997.
3. Lai, S. L., Goldstein, L. J., Gottesmann, M. M., Pastan, I., Tsai, C. M., Johnson, B. E., et al. MDR1 gene expression in lung cancer. J. Natl. Cancer Inst., 81: 1144-1145, 1989.
4. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D., and Roninson, I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst., 84: 1486-1491, 1992.
5. Giaccone, G., van Ark-Otte, J., Scagliotti, G., Capranico, G., van der Valk, P., Rubio, G., et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim. Biophys. Acta, 1264: 337-346, 1995.
6. Kreipe, H., Heidebrecht, H. J., Hansen, S., Rohlk, S., Kubbies, M., Wacker, H. H., et al. A new proliferation associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am. J. Pathol, 142: 3-9, 1993.
7. Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 83: 517-530, 1994.
8. Klumper, E., Giaccone, G., Pieters, R., Broekema, G., van Ark-Otte, J., van Wering, E. R., et al. Topoisomerase IIαa gene expression in childhood acute lymphoblastic leukemia. Leukemia (Baltimore), 9: 1653-1660, 1995.
9. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2: 209-214, 1991.
10. Giaccone, G., Gazdar, A. F., Beck, H., Zunino, F., and Capranico, G. The multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res., 52: 1666-1674, 1992.
11. de Jong, S., Zijlstra, J. G., de Vries, E. G. E., and Mulder, N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 50: 304-309, 1990.
12. 4. Br. J. Cancer, 74: 1869-1876, 1996.
13. Markovits, J., Junqua, S., Goldwasser, F., Venuat A-M., Luccioni, C., Beaumatin, J., et al. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase IIβb isoform. Biochem. Pharmacol., 50: 177-186, 1995.
14. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
15. Giaccone, G., van Ark-Otte, J., Rubio, G. J., Gazdar, A. F., Broxterrnan, H. J., Dingemans, A. M. C., et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. Int. J. Cancer, 66: 760-767, 1996.
16. Nooter, K., Bosman, F. T., Burger, H., van Wingerden, K. E., Flens, M. J., Scheper, R. J., et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann. Oncol., 7: 75-81, 1996.
17. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., et al. p21 RNA and protein expression in non-small cell lung carcinoma: evidence of p53- independent expression and association with tumoral differentiation. Oncogene, 12: 1319-1324, 1996.
18. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., et al. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
19. Miller, C. W., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C. H. C. M., et al. HP. p53 mutations in human lung tumors. Cancer Res., 52: 1695-1698, 1992.
20. Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6: 1775-1778, 1991.
21. Ikegaki, N., Katsumata, M., Minna, J., and Tsujimoto, Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res., 54: 6-8, 1994.
22. Yan J-J., Chen F-F., Tsai Y-C., and Jin, Y-T. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology, 53: 6-11, 1996.
23. Reeve, J. G., Xiong, J., Morgan, J., and Bleehen, N. M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer, 73: 1193-1200, 1996.
24. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Crossman, J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effect on events subsequent to topoisomerase-II induced DNA strand breaks and their repair. Cancer Res., 53: 4251-4256, 1993.
25. Ohmori, T., Podack, E. R., Nishio, K., Takahashi, M., Miyahara, Y., Takeda, Y., et al. Apoptosis of lung cancer cells caused by some anticancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2. Biochem. Biophys. Res. Commun., 192: 30-36, 1993.
26. Miller, A. B., Hogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
27. Kreipe, H., Alm, P., Olsson, H., Hauberg, M., Fischer, L., and Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am. J. Pathol., 142: 651-657, 1993.
28. Kimura, K., Nozaki, N., Enomoto, T., Tanaka, M., and Kikuchi, A. Analysis of M phase specific phosphorylation of DNA topoisomerase II. J. Biol. Chem., 271: 21439-21445, 1996.
29. Pezzella, F., Tse, A. G. D., Cordell, J. L., Pulford, K. A. F., Gatter, K. C., and Mason, D. Y. Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am. J. Pathol., 137: 225-232, 1990.
30. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J., et al. Immunochemical detection of the multidrug resistance-associated protein (MRP) in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
31. Hsu, S. M., Raine, L., and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
32. Izquierdo, M. A., van der Zee, A. G., Vermorken, J. B., van der Valk, P., Belien, J. A., Giaccone, G., et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87: 1230-1237, 1995.
33. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Tagaki, Y., et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J. Clin. Oncol., 14: 497-502, 1996.
34. CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90: 1072-1079, 1998.
35. Takayama, K., Ogata, K., Nakanishi, Y., et al. Bcl-2 expression as a predictor of chemosensitivities and survival I small cell lung cancer. Cancer J. Sci. Am., 2: 212-216, 1996.
36. Altman D. G. Practical statistics for medical research. New York: Chapman and Hall, 1991.
37. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
38. Linn, S. C., Pinedo, H. M., van Ark-Otte, J., var der Valk, P., Hoekman, K., Honkoop, A. H., et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer, 71: 787-795, 1997.
39. Rubin, E. H., Li, T. K., Duann, P., and Liu, L. F. Cellular resistance to topoisomerase poisons. Cancer Treat. Res., 87: 243-260, 1996.
40. Guinee, D. G., Holden, J. A., Benfield, J. R., Woodward, M. L., Przygodzki, R. M., Fishback, N. F., et al. Comparison of DNA topoisomerase IIαa expression in small cell and nonsmall cell carcinoma of the lung in search of a mechanism of chemotherapeutic response. Cancer (Phila.), 78: 729-735, 1996.
41. Capranico, G., Giaccone, G., Zunino, F., Garattini, S., and D'Incalci. M. DNA topoisomerase II poisons and inhibitors. In: H. M. Pinedo, D. L. Longo, and B. A. Chabner (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual, Vol. 17, pp. 114-131. Amsterdam: Elsevier Science Publishers, 1997.
42. Wang, O., Zambetti, G. P., and Suttle, D. P. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol. Cell. Biol., 17: 389-397, 1997.
43. Sandri, M. I., Isaacs, R. J., Ongkeko, W. M., Harris, A. L., Hickson, I. D., Broggini, M., et al. p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res., 24: 4464-4470, 1996.
44. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
45. Mirski, S. E. L., and Cole, S. P. C. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res, 55: 2129-2134, 1995.
46. Wessel, I., Jensen, P. B., Falck, J., Mirski, S. E. L., Cole, S. P. S., and Sehested, M. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIαa in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res., 57: 4451-4454, 1997.
47. Savaraj, N., Wu, C. J., Xu, R., Lampidis, T., Lai, S., Donnelly, E., et al. Multidrug-resistant gene expression in small-cell lung cancer. Am. J. Clin. Oncol., 20: 398-403, 1997.
48. Beck, W. T., Grogan, T. M., Willman, C. L., Cordon-Cardo, C., Parham, D. M., Kuttesch, J. F., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res., 56: 3010-3020, 1996.
49. Boege, F., Andersen, A., Jensen, S., Zeidler, R., and Kreipe, H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα. Am. J. Pathol., 146: 1302-1308, 1995.
50. Sandri, M. I., Hochhauser, D., Ayton, P., Camplejohn, R. C., Whitehouse, R., Turley, H., et al. Differential expression of the topoisomerase IIαa and βb genes in human breast cancers. Br. J. Cancer, 73: 1518-1524, 1996.
51. 1 arrest in UV-irradiated human skin fibroblasts. Cancer Res., 57: 3390-3394, 1997.
52. Stefanaki, K., Rontogiannis, D., Vamvouka, C., Bolioti, S., Chaniotis, V., Sotsiou, F., et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res., 18: 1167-1174, 1998.
53. Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nagakawa, K., et al. p21 expression as a predictor for favorable prognosis in squamous carcinoma of the lung. Clin. Cancer Res., 3: 1831-1835, 1997.
54. Ben-Ezra, J. M., Kornstein, M. J., Grimes, M. M., and Krystal, G. Small cell carcinomas of the lung express the bcl-2 protein. Am. J. Pathol., 145: 1036-1040, 1994.
55. Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A. M. C., et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol., 15: 2456-2466, 1997.
56. Kaiser, U., Schilli, M., Haag, U., Neumann, K., Kreipe, H., Kogan, E., et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer, 15: 31-40, 1996.
57. Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D-B., Richards, W., et al. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J. Clin. Oncol., 16: 2468-2477, 1998.
58. Gallo, O., Boddi, V., Calzolari, A., Simonetti, L., Trovati, M., and Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin. Cancer Res., 2: 261-267, 1996.
59. Krajewzki, S., Chatten, J., Hanada, M., and Reed, J. C. Immunohistochemical analysis of the bcl-2 oncoprotein in human neuroblastoma. Lab. Invest., 2: 42-54, 1995.
60. Brown, R. The bcl-2 family of proteins. Br. Med. Bull., 53: 466-477, 1996.